Citadel Advisors’s LENZ Therapeutics LENZ Stock Holding History

Citadel Advisors’s Portfolio LENZ Stock Details LENZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$618K	Buy	108,800 +30,400	+39%	+$245K	﹤0.01%	9361
2026 Q1	$717K	Sell	78,400 -3,700	-5%	-$52K	﹤0.01%	8445
2025 Q4	$1.31M	Buy	82,100 +57,200	+230%	+$1.67M	﹤0.01%	6805
2025 Q3	$1.16M	Buy	24,900 +14,500	+139%	+$533K	﹤0.01%	7211
2025 Q2	$305K	Buy	+10,400	New	+$283K	﹤0.01%	9784
2024 Q1	–	Sell	-243	Closed	-$4.45K	–	15567
2023 Q4	$4.45K	Buy	243 +172	+242%	+$2.84K	﹤0.01%	13504
2023 Q3	$1.24K	Sell	71 -472	-87%	-$8.21K	﹤0.01%	13893
2023 Q2	$9.88K	Sell	543 -1,028	-65%	-$20.5K	﹤0.01%	13234
2023 Q1	$26.9K	Sell	1,571 -1,600	-50%	-$25.9K	﹤0.01%	12830
2022 Q4	$73.7K	Sell	3,171 -1,929	-38%	-$44.7K	﹤0.01%	11642
2022 Q3	$113K	Buy	5,100 +3,429	+205%	+$81.7K	﹤0.01%	10990
2022 Q2	$32K	Buy	+1,671	New	+$37.3K	﹤0.01%	12186

Other funds holding LENZ

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

AWG

Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

7IH

72 Investment Holdings Stamford, Connecticut $50M AUM 647.58% 1-Year Est. Return

Citadel Advisors's LENZ Position: Q2 2026 in Review

Citadel Advisors opened a new position in LENZ Therapeutics (LENZ) in Q2 2026: 363,229 shares worth $2.06M. The stake represents ﹤0.01% of the portfolio and ranks #6473 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in LENZ as recently as Q4 2025.

Citadel Advisors first reported a position in LENZ in Q2 2021 and has held it in 16 quarters since. The position peaked at $38.9M in Q2 2021. 145 funds tracked by Wall St. Rank hold LENZ as of Q2 2026.

Citadel Advisors held 363,229 shares of LENZ Therapeutics worth $2.06M as of Q2 2026.
LENZ Therapeutics was a new Citadel Advisors position in Q2 2026.
LENZ Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #6473 holding.
Citadel Advisors first reported a position in LENZ Therapeutics in Q2 2021 and has held it in 16 quarters since.
Citadel Advisors's LENZ Therapeutics position peaked at $38.9M in Q2 2021.
145 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.